Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postpartum TMA requiring dialysis with discordant complement tests: a case report.

CEN case reports·2026
Same author

Urinary Microcholesterol and Adverse Kidney Outcomes in CKD.

Kidney international reports·2026
Same author

EXPRESS: Fibroblast Activation Protein Protects the Ischemic Brain Through Regulation of Post-Ischemic Inflammation.

Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism·2026
Same author

Preplanned versus online control in baseball batting: Effects of temporal constraints and spatial uncertainty.

Journal of experimental psychology. Human perception and performance·2026
Same author

Lower-dose glucocorticoid therapy achieves comparable outcomes in Japanese patients with lupus nephritis.

Lupus·2026
Same author

Multicellular Crosstalk and Therapeutic Vaccines in Heart Failure.

Physiology (Bethesda, Md.)·2026

Related Experiment Video

Updated: May 29, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

A RANKL-derived Peptide Inhibits RSPO3-LGR4-Wnt Signaling and Lung Adenocarcinoma in Mice.

Nan Ju1, Hiroki Hayashi2, Chinyang Chang1

  • 1Department of Gene & Stem Cell Regenerative Therapy, Graduate School of Medicine, The University of Osaka, Suita, Japan.

Anticancer Research
|May 27, 2026
PubMed
Summary
This summary is machine-generated.

MHP1-AcN, a novel peptide, effectively inhibits lung adenocarcinoma growth and metastasis by targeting the RSPO3-LGR4-Wnt pathway. This peptide acts as an LGR4 antagonist, reducing tumor progression and offering therapeutic potential.

Keywords:
LGR4Lung adenocarcinomaR-spondinRANKL

More Related Videos

The Soft Agar Colony Formation Assay
08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

Related Experiment Videos

Last Updated: May 29, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

The Soft Agar Colony Formation Assay
08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
10:32

Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs

Published on: December 19, 2019

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer is a leading cause of cancer mortality despite treatment advances.
  • RSPO3-LGR4 signaling drives tumor progression in lung adenocarcinoma by activating Wnt signaling.
  • LGR4 also serves as a receptor for RANKL, a target for the peptide MHP1-AcN.

Purpose of the Study:

  • To investigate if MHP1-AcN targets LGR4.
  • To determine the effects of MHP1-AcN on RSPO3-LGR4 signaling in lung cancer cells.
  • To evaluate MHP1-AcN as a potential therapeutic agent for lung adenocarcinoma.

Main Methods:

  • A549 lung cancer xenograft model in mice treated with MHP1-AcN.
  • In vitro assessment of MHP1-AcN's effects on cell proliferation, cytotoxicity, migration, and invasion.
  • Analysis of molecular interactions and signaling pathways using immunoprecipitation and immunoblotting.

Main Results:

  • MHP1-AcN significantly reduced tumor volume and weight in vivo.
  • MHP1-AcN directly interacted with LGR4, disrupting RSPO3-LGR4 complex formation and inhibiting Wnt signaling.
  • MHP1-AcN suppressed cell proliferation, migration, and invasion, with no observed cytotoxicity.

Conclusions:

  • MHP1-AcN acts as a novel LGR4 antagonist.
  • MHP1-AcN effectively inhibits RSPO3-LGR4-Wnt signaling, tumor growth, and metastasis in lung adenocarcinoma.
  • MHP1-AcN shows potential as a therapeutic agent for targeting this pathway in lung cancer.